OLEMA PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-63.2M | $-53.1M | $-46.1M | $-42.2M | $-43.8M | $-30.4M | $-33.6M | $-34.6M |
| Depreciation & Amortization | $102.0K | $119.0K | $187.0K | $43.0K | $132.0K | $128.0K | $116.0K | $95.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $12.9M | $10.1M | $4.3M | $4.3M | $4.7M | $4.4M | $6.3M | $5.6M |
| Net Cash from Operating Activities | $-45.9M | $-46.0M | $-38.3M | $-34.5M | $-29.9M | $-44.0M | $-26.3M | $-27.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $0 | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $40.8M | $4.5M | $-162.2M | $17.3M | $34.2M | $-45.1M | $-114.4M | $45.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.1M | $45.7M | $213.6M | $41.0K | $-2.5M | $222.0K | $244.3M | $92.0K |
| Net Change in Cash | $-3.9M | $4.2M | $13.0M | $-17.2M | $1.8M | $-88.8M | $103.6M | $19.0M |
| Free Cash Flow | — | — | — | — | — | — | $-26.3M | $-27.0M |